AU2003249722A1 - Therapeutic amides - Google Patents

Therapeutic amides

Info

Publication number
AU2003249722A1
AU2003249722A1 AU2003249722A AU2003249722A AU2003249722A1 AU 2003249722 A1 AU2003249722 A1 AU 2003249722A1 AU 2003249722 A AU2003249722 A AU 2003249722A AU 2003249722 A AU2003249722 A AU 2003249722A AU 2003249722 A1 AU2003249722 A1 AU 2003249722A1
Authority
AU
Australia
Prior art keywords
amides
therapeutic amides
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003249722A
Other languages
English (en)
Inventor
Thomas H. Corbett
Stuart T. Hazeldine
Jerome P. Horwitz
Eduardo Palomino
Lisa Polin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of AU2003249722A1 publication Critical patent/AU2003249722A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
AU2003249722A 2002-07-03 2003-07-03 Therapeutic amides Abandoned AU2003249722A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39385802P 2002-07-03 2002-07-03
US60/393,858 2002-07-03
PCT/US2003/021126 WO2004004651A2 (en) 2002-07-03 2003-07-03 Therapeutic amides

Publications (1)

Publication Number Publication Date
AU2003249722A1 true AU2003249722A1 (en) 2004-01-23

Family

ID=30115656

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003249704A Ceased AU2003249704B2 (en) 2002-07-03 2003-07-03 A-'7-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
AU2003249722A Abandoned AU2003249722A1 (en) 2002-07-03 2003-07-03 Therapeutic amides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2003249704A Ceased AU2003249704B2 (en) 2002-07-03 2003-07-03 A-'7-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents

Country Status (18)

Country Link
US (3) US7109341B2 (enExample)
EP (1) EP1539699A1 (enExample)
JP (1) JP2005532397A (enExample)
CN (1) CN1688547A (enExample)
AU (2) AU2003249704B2 (enExample)
BR (1) BR0311491A (enExample)
CA (1) CA2491612C (enExample)
EA (1) EA009679B1 (enExample)
GE (1) GEP20074058B (enExample)
IL (1) IL164555A0 (enExample)
MX (1) MXPA05000233A (enExample)
NO (1) NO20050573L (enExample)
NZ (1) NZ535887A (enExample)
PL (1) PL373624A1 (enExample)
SG (1) SG145570A1 (enExample)
UA (1) UA79293C2 (enExample)
WO (2) WO2004005260A1 (enExample)
ZA (1) ZA200408191B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75691C2 (en) * 2001-07-31 2006-05-15 Univ Wayne State Quinoline derivatives, use thereof as antitumor drugs, composition based thereon and therapeutical method for treatment of cancer
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
US20040106662A1 (en) * 2002-08-24 2004-06-03 Herbert Irschik Use of the disorazoles and their derivatives for the treatment of benign and malignant oncoses
CN100427482C (zh) * 2005-08-01 2008-10-22 复旦大学 N,n-二甲胺酰基-2,3-二呋喃基-6-氨基喹噁啉,其制备方法与应用
US20070054938A1 (en) * 2005-09-07 2007-03-08 Horwitz Jerome P Antitumor agents
US8183379B2 (en) * 2005-09-07 2012-05-22 Wayne State University Antitumor agents
US7470788B2 (en) * 2005-09-07 2008-12-30 Wayne State University Antitumor agents
EP1897542A1 (en) * 2006-09-07 2008-03-12 Sanofi-Aventis Aqueous formulation comprising an antitumor agent
US9096546B2 (en) * 2007-05-10 2015-08-04 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9096544B2 (en) 2009-12-23 2015-08-04 Wayne State University Therapeutic compounds
CN103127112A (zh) * 2013-02-27 2013-06-05 江苏先声药物研究有限公司 一类喹啉酮衍生物在肿瘤治疗中的应用
CN105085480B (zh) * 2014-05-16 2017-12-29 湖南大学 2‑[4‑（喹喔啉‑2‑氧基）苯氧基]脂肪酰吡啶胺的医药用途
CN105085506B (zh) * 2014-05-16 2018-01-19 湖南大学 2‑[4‑(苯并噁唑‑2‑氧基)苯氧基]脂肪酰吡啶胺的医药用途
CN107827828B (zh) * 2017-11-21 2021-03-30 南京华漫新材料科技有限公司 含苯酰肼骨架的喹喔啉衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用
TWI826034B (zh) * 2022-10-07 2023-12-11 宏碁股份有限公司 影像過曝改善方法及電子裝置

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54112628A (en) 1978-02-23 1979-09-03 Canon Inc Electromagnetic driving device
JPS6033389B2 (ja) * 1979-02-22 1985-08-02 日産化学工業株式会社 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤
US5364831A (en) * 1980-08-06 1994-11-15 Nissan Chemical Industries Ltd. Quinoxaline derivatives and herbicidal composition
US6197728B1 (en) * 1980-08-06 2001-03-06 Nissan Chemical Industries Ltd. Quinoxaline derivatives and herbicidal composition
US4760066A (en) * 1982-09-21 1988-07-26 Wayne State University Method for treating human tumor cell metastasis
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4710507A (en) * 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
US5250690A (en) * 1985-05-02 1993-10-05 Dowelanco Haloalkoxy anilide derivatives of 2-4(-heterocyclic oxyphenoxy)alkanoic or alkenoic acids and their use as herbicides
JPS62190172A (ja) * 1986-02-14 1987-08-20 Teijin Ltd フエノキシ脂肪族カルボン酸誘導体および除草剤
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1994013647A1 (en) * 1992-12-15 1994-06-23 The Du Pont Merck Pharmaceutical Company (2-quinoxalinyloxy)phenoxypropanoic acids and related derivatives as anticancer agents
US6680311B1 (en) * 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
AU4233997A (en) * 1996-08-30 1998-03-19 Eli Lilly And Company Process for preparing pharmaceutical compounds
CA2264245A1 (en) * 1996-09-06 1998-03-12 Eli Lilly And Company Process to prepare pharmaceutical compounds
US6160006A (en) * 1996-10-18 2000-12-12 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit
US6352991B1 (en) * 1997-01-08 2002-03-05 Wayne State University 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
US6238644B1 (en) * 1997-09-03 2001-05-29 Wayne State University Method for treating and/or imaging breast cancer using radioactive iodide
US6586461B1 (en) * 1998-06-16 2003-07-01 Wayne State University Prenyl transferase inhibitors
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
DE60114022T2 (de) * 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit Matrix metalloproteinase-inhibitoren
US6747021B2 (en) * 2000-10-02 2004-06-08 Eli Lilly And Company Cryptophycin compound
UA75691C2 (en) * 2001-07-31 2006-05-15 Univ Wayne State Quinoline derivatives, use thereof as antitumor drugs, composition based thereon and therapeutical method for treatment of cancer
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents

Also Published As

Publication number Publication date
GEP20074058B (en) 2007-03-12
PL373624A1 (en) 2005-09-05
US7585863B2 (en) 2009-09-08
ZA200408191B (en) 2006-07-26
SG145570A1 (en) 2008-09-29
WO2004005260A1 (en) 2004-01-15
MXPA05000233A (es) 2005-04-11
UA79293C2 (en) 2007-06-11
CA2491612A1 (en) 2004-01-15
US7728007B2 (en) 2010-06-01
US7109341B2 (en) 2006-09-19
WO2004004651A2 (en) 2004-01-15
EP1539699A1 (en) 2005-06-15
BR0311491A (pt) 2005-04-26
US20090076073A1 (en) 2009-03-19
US20060293333A1 (en) 2006-12-28
CA2491612C (en) 2012-01-03
NO20050573L (no) 2005-02-02
JP2005532397A (ja) 2005-10-27
AU2003249704A1 (en) 2004-01-23
US20040132618A1 (en) 2004-07-08
AU2003249704B2 (en) 2010-05-20
EA009679B1 (ru) 2008-02-28
NZ535887A (en) 2006-11-30
IL164555A0 (en) 2005-12-18
CN1688547A (zh) 2005-10-26
EA200500095A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
AU2003239909A1 (en) Enhanced-service provision
AU2003256378A1 (en) Therapeutic pack
GB0206876D0 (en) Therapeutic agents
AU2003280511A1 (en) Vibrator
AU2003279911A1 (en) Therapeutic formulations
AU2003235123A1 (en) Unit
AU2003249722A1 (en) Therapeutic amides
AUPS160602A0 (en) Therapeutic method
AU2003247005A1 (en) Therapy combination
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
GB0219660D0 (en) Therapeutic use
AU2003215150A1 (en) Therapeutic compounds
AU2003201863A1 (en) Potential therapeutic device
AU2003261439A1 (en) Massage device
GB0203431D0 (en) Gel
AU2003298582A1 (en) Therapeutic guanidines
AU2003234867A1 (en) Rollator
AU2003253499A1 (en) Massage device
AU2003231937A1 (en) Therapeutic methods
AU2002953515A0 (en) Therapeutic compounds - II
GB0213383D0 (en) Therapeutic conditions
AU2002952968A0 (en) Therapeutic agents
HK1081526A (en) Therapeutic agents
AU2002953547A0 (en) Therapeutic combination
AU2003251456A1 (en) N-bisaryl- and n-aryl-cycloalkylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase